Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
This observational or N/A phase trial investigates Epilepsy and Glioma and is currently ongoing. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) leads this study, which shows 11 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
May 2022 — Jul 2024 [monthly]
Unknown Status
-
Dec 2021 — May 2022 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: PHASE4 → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status PHASE4
First recorded
Apr 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Amsterdam UMC, location VUmc
- Medical Center Haaglanden
For direct contact, visit the study record on ClinicalTrials.gov .